Frank Yocca, Chief Scientific Officer at BioXcel Therapeutics (NASDAQ:BTAI), sold 6,845 shares of common stock for a total of $7,426.
The transaction occurred on May 20, 2026, with prices ranging from $1.07 to $1.105 per share.
The sale was executed under a Rule 10b5-1 trading plan adopted on February 3, 2026.
The stock currently trades at $1.13, near its 52-week low of $1.01.
According to Bond.az analysis, the stock appears undervalued at current levels.












